Paradoxical Antibiotic Effect of Ampicillin: Use of a Population Pharmacokinetic Model to Evaluate a Clinical Correlate of the Eagle Effect in Infants With Bacteremia.


Journal

The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858

Informations de publication

Date de publication:
08 2020
Historique:
pubmed: 3 4 2020
medline: 16 7 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

High doses of ampicillin are often used to achieve therapeutic drug concentrations in infants. A paradoxical antibiotic effect, often called the Eagle effect, occurs when increasing concentrations of antibiotic above a threshold results in decreased efficacy. It is unknown if infants treated with ampicillin are at risk for this paradoxical effect. We identified infants <28 days of age with Escherichia coli, Enterococcus or Streptococcus agalactiae (group B streptococcus) bloodstream infections from 1997 to 2012 and previously included in an ampicillin pharmacokinetic (PK) modeling study. We compared the odds of death for ampicillin dose, estimated time above the minimum inhibitory concentration (T > MIC) and PK parameters using separate logistic regression models. Adjusted logistic regression and Poisson models were used to calculate the odds of prolonged bacteremia ≥3 days and the duration of bacteremia, respectively, for dose, T > MIC and multiple PK parameters. Among 1272 infants meeting inclusion criteria, odds of death 7 or 30 days after the positive blood culture were not consistent with a paradoxical effect across any of the dosing regimens or PK parameters evaluated. The odds of prolonged bacteremia was lowest at the lowest dose category and the lowest daily dose category but not associated with the area-under-the-concentration time curve from 0 to 24 hours, or the maximum or minimum concentrations at steady state. T > MIC of ≥50% of the dosing interval was associated with decreased duration of bacteremia and odds of prolonged bacteremia. It is unlikely that a paradoxical antibiotic effect will have a clinical correlate when ampicillin is used for neonatal bacteremia. A T > MIC ≥50% decreased both duration of bacteremia and odds of prolonged bacteremia.

Sections du résumé

BACKGROUND
High doses of ampicillin are often used to achieve therapeutic drug concentrations in infants. A paradoxical antibiotic effect, often called the Eagle effect, occurs when increasing concentrations of antibiotic above a threshold results in decreased efficacy. It is unknown if infants treated with ampicillin are at risk for this paradoxical effect.
METHODS
We identified infants <28 days of age with Escherichia coli, Enterococcus or Streptococcus agalactiae (group B streptococcus) bloodstream infections from 1997 to 2012 and previously included in an ampicillin pharmacokinetic (PK) modeling study. We compared the odds of death for ampicillin dose, estimated time above the minimum inhibitory concentration (T > MIC) and PK parameters using separate logistic regression models. Adjusted logistic regression and Poisson models were used to calculate the odds of prolonged bacteremia ≥3 days and the duration of bacteremia, respectively, for dose, T > MIC and multiple PK parameters.
RESULTS
Among 1272 infants meeting inclusion criteria, odds of death 7 or 30 days after the positive blood culture were not consistent with a paradoxical effect across any of the dosing regimens or PK parameters evaluated. The odds of prolonged bacteremia was lowest at the lowest dose category and the lowest daily dose category but not associated with the area-under-the-concentration time curve from 0 to 24 hours, or the maximum or minimum concentrations at steady state. T > MIC of ≥50% of the dosing interval was associated with decreased duration of bacteremia and odds of prolonged bacteremia.
CONCLUSIONS
It is unlikely that a paradoxical antibiotic effect will have a clinical correlate when ampicillin is used for neonatal bacteremia. A T > MIC ≥50% decreased both duration of bacteremia and odds of prolonged bacteremia.

Identifiants

pubmed: 32235247
doi: 10.1097/INF.0000000000002663
pii: 00006454-202008000-00017
pmc: PMC8628496
mid: NIHMS1608761
doi:

Substances chimiques

Anti-Bacterial Agents 0
Ampicillin 7C782967RD

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

725-729

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR002015
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002014
Pays : United States

Références

J Antimicrob Chemother. 1979 Sep;5(5):613-6
pubmed: 500518
Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S518-22
pubmed: 3025999
Int J Antimicrob Agents. 2008 Apr;31(4):345-51
pubmed: 18313273
Pediatrics. 2010 Feb;125(2):e214-24
pubmed: 20100760
Clin Infect Dis. 1998 Jul;27(1):10-22
pubmed: 9675443
Antimicrob Agents Chemother. 1987 Jul;31(7):1014-6
pubmed: 2821883
Antimicrob Agents Chemother. 2014 Jun;58(6):3013-20
pubmed: 24614374
Pediatr Infect Dis J. 1993 Dec;12(12):973-5
pubmed: 8108222
Pediatr Infect Dis J. 1993 Dec;12(12 Suppl 3):S118-21
pubmed: 8295812
Pediatrics. 2006 Jun;117(6):1979-87
pubmed: 16740839
Chemotherapy. 1987;33(5):331-9
pubmed: 3665632
Pediatr Infect Dis J. 1996 Mar;15(3):255-9
pubmed: 8852915
Science. 1948 Jan 9;107(2767):44-5
pubmed: 17778247
J Clin Microbiol. 2019 May 24;57(6):
pubmed: 30971460
J Antimicrob Chemother. 1985 Apr;15(4):507-8
pubmed: 4008382
Antimicrob Agents Chemother. 2007 Sep;51(9):3449-51
pubmed: 17576831
Crit Care Resusc. 2014 Sep;16(3):190-6
pubmed: 25161021
Clin Ther. 2005 Nov;27(11):1820-30
pubmed: 16368453
Chemotherapy. 1981;27(5):313-7
pubmed: 7021076
J Infect Dis. 2005 Jun 15;191(12):2118-20
pubmed: 15897998
N Engl J Med. 1953 Mar 19;248(12):481-8
pubmed: 13036982
J Antimicrob Chemother. 1994 Mar;33(3):585-93
pubmed: 8040122
J Perinatol. 2011 Jul;31(7):477-80
pubmed: 21372796
Antimicrob Agents Chemother. 1992 Mar;36(3):540-4
pubmed: 1622162
J Pediatr. 2019 May;208:214-220.e2
pubmed: 30879729
Pediatr Blood Cancer. 2015 Mar;62(3):477-82
pubmed: 25328131
J Exp Med. 1948 Jul;88(1):99-131
pubmed: 18871882
Antimicrob Agents Chemother. 1990 Dec;34(12):2331-6
pubmed: 1708224
J Pediatr. 2016 Nov;178:125-129.e1
pubmed: 27522443
Pediatrics. 2011 Nov;128(5):e1242-9
pubmed: 22025597
Ann Pharmacother. 1998 Apr;32(4):482-4
pubmed: 9562146
J Infect Dis. 1988 Jul;158(1):23-8
pubmed: 3292661
Diagn Microbiol Infect Dis. 1996 Aug;25(4):213-7
pubmed: 8937847
J Antimicrob Chemother. 1986 May;17(5):684-5
pubmed: 3722039
Indian J Pediatr. 2015 Jan;82(1):71-9
pubmed: 25319813
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30833428
Am J Med. 1950 Sep;9(3):280-99
pubmed: 14771084
Diagn Microbiol Infect Dis. 2018 Jul;91(3):294-297
pubmed: 29661528
Pediatrics. 1979 Nov;64(5):627-31
pubmed: 492836
J Pediatr. 1974 Apr;84(4):571-7
pubmed: 4600568
Am J Perinatol. 2014 Oct;31(9):811-21
pubmed: 24347262
J Infect Dis. 1974 Apr;129(4):461-4
pubmed: 4206248

Auteurs

Jessica E Ericson (JE)

From the Department of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania.

Christoph P Hornik (CP)

Department of Pediatrics, Duke University, Durham, North Carolina.
Duke Clinical Research Institute, Duke University, Durham, North Carolina.

Rachel G Greenberg (RG)

Department of Pediatrics, Duke University, Durham, North Carolina.
Duke Clinical Research Institute, Duke University, Durham, North Carolina.

Reese H Clark (RH)

Pediatrix-Obstetrix Center for Research and Education, Sunrise, Florida.

Adriana H Tremoulet (AH)

Department of Pediatrics, University of California, San Diego, La Jolla, California.

Jennifer Le (J)

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, California.

Michael Cohen-Wolkowiez (M)

Department of Pediatrics, Duke University, Durham, North Carolina.
Duke Clinical Research Institute, Duke University, Durham, North Carolina.

P Brian Smith (PB)

Department of Pediatrics, Duke University, Durham, North Carolina.
Duke Clinical Research Institute, Duke University, Durham, North Carolina.

Daniel K Benjamin (DK)

Department of Pediatrics, Duke University, Durham, North Carolina.
Duke Clinical Research Institute, Duke University, Durham, North Carolina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH